<DOC>
	<DOCNO>NCT00918645</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , radionuclide image use calcium-41 ( 41Ca ) chloride aqueous solution , may help predict progressive disease patient prostate cancer bone metastasis . PURPOSE : This clinical trial study well calcium-41 ( 41Ca ) chloride aqueous solution work diagnose patient prostate cancer bone metastasis .</brief_summary>
	<brief_title>Calcium-41 ( 41Ca ) Chloride Aqueous Solution Diagnosing Patients With Prostate Cancer Bone Metastasis</brief_title>
	<detailed_description>OBJECTIVES : Primary - To measure pharmacokinetics single oral dose calcium-41 ( 41Ca ) chloride aqueous solution ( ^41Ca ) 18 month patient hormone-refractory prostate cancer bone metastasis . - To correlate ^41Ca-tracer kinetics time disease progression , skeletal-related event , death . Secondary - To correlate modulation baseline urinary ^41Ca clearance change clinically relevant disease parameter , include isotope bone scan data PSA . - To combine bone turnover assessment ^41Ca collagen/bone cell biomarkers clinical image technique , especially isotope bone scan , provide improve stratification disease stage . OUTLINE : Patients receive oral calcium-41 ( 41Ca ) chloride aqueous solution ( ^41Ca ) day 1 . Some patient also receive oral calcium-46 ( 46Ca ) chloride aqueous solution ( ^46Ca ) . Urine blood specimen collect periodically 18 month . Blood sample assay bone collagen residue , bone alkaline phosphatase , PSA . Urine specimens assess ^41Ca/Ca . Isotope bone scintigraphy use measure radioactivity . After completion study treatment , patient follow periodically 3 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<criteria>Eligibility Criteria Histologically cytologically confirm prostate cancer Gleason score available interpretable Prostate cancer deem hormone refractory androgen independent within past 12 month Evidence bony metastasis Either receive bisphosphonate therapy receive bisphosphonate within last 18 month . Participants bisphosphonate therapy receive within last 18 month currently Denosumab therapy . All anticancer therapy allow . Age &gt; 18 year ECOG performance status 02 ( Karnofsky &gt; 50 % ) . Life expectancy 6 month great . Investigators encourage follow good medical practice assure participant adequate hematologic , hepatic , renal function . Recent plan isotope bone scan , within 12 month prior enrollment . Ability understand willingness sign write informed consent document . Exclusion Criteria Participants exclude experience severe skeletal related event ( SRE ) within past 3 month . For study , SRE consist follow : palliative radiotherapy bone , pathologic fracture , spinal cord compression , hypercalcemia malignancy , surgery bone treat prevent fracture . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , interstitial lung disease , chronic kidney disease , hyperthyroidism , psychiatric illness/social situation would limit compliance study requirement . Corrected serum calcium &lt; 8.0 mg/dL ( 2.0 mmol/L ) â‰¥12.0 mg/dL ( 3.0 mmol/L )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>bone metastasis</keyword>
</DOC>